Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Antimicrobial Resistance Gene Prevalence in a Population of Patients with Advanced Dementia Is Related to Specific Pathobionts.

Rowan-Nash AD, Araos R, D'Agata EMC, Belenky P.

iScience. 2020 Feb 13;23(3):100905. doi: 10.1016/j.isci.2020.100905. [Epub ahead of print]

PMID:
32106056
2.

A clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa (IRONIC study).

Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Paz Morales H, Brunel AS, García E, Isler B, Kern WV, Morales I, Maestro-de la Calle G, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmatti P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J; IRONIC study group.

Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02494-19. doi: 10.1128/AAC.02494-19. [Epub ahead of print]

PMID:
32015035
3.

Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam.

Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, Munita JM, Boté A, Gasch O, Nuvials X, Dinh A, Shaw R, Lomas JM, Torres V, Castón J, Araos R, Abbo LM, Rakita R, Pérez F, Aitken SL, Arias CA, Martín-Pena ML, Colomar A, Núñez MB, Mensa J, Martínez JA, Soriano A.

Open Forum Infect Dis. 2019 Sep 28;6(10):ofz416. doi: 10.1093/ofid/ofz416. eCollection 2019 Oct.

4.

Fecal Microbiome Characteristics and the Resistome Associated With Acquisition of Multidrug-Resistant Organisms Among Elderly Subjects.

Araos R, Battaglia T, Ugalde JA, Rojas-Herrera M, Blaser MJ, D'Agata EMC.

Front Microbiol. 2019 Sep 27;10:2260. doi: 10.3389/fmicb.2019.02260. eCollection 2019.

5.

Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): study protocol of a retrospective multicentre international study.

Albasanz-Puig A, Gudiol C, Parody R, Tebe C, Akova M, Araos R, Bote A, Brunel AS, Calik S, Drgona L, García E, Hemmati P, Herrera F, Ibrahim KY, Isler B, Kanj S, Kern W, Maestro de la Calle G, Manzur A, Marin JI, Márquez-Gómez I, Martín-Dávila P, Mikulska M, Montejo JM, Montero M, Morales HMP, Morales I, Novo A, Oltolini C, Peghin M, Del Pozo JL, Puerta-Alcalde P, Ruiz-Camps I, Sipahi OR, Tilley R, Yáñez L, Gomes MZR, Carratalà J; IRONIC study group.

BMJ Open. 2019 May 24;9(5):e025744. doi: 10.1136/bmjopen-2018-025744.

6.

The human microbiota and infection prevention.

Araos R, D'Agata EMC.

Infect Control Hosp Epidemiol. 2019 May;40(5):585-589. doi: 10.1017/ice.2019.28. Epub 2019 Feb 19.

PMID:
30777586
7.

Acquisition of Multidrug-resistant Organisms in the Absence of Antimicrobials.

D'Agata EMC, Varu A, Geffert SF, Araos R, Mitchell S, Situ A, Cameron C.

Clin Infect Dis. 2018 Oct 15;67(9):1437-1440. doi: 10.1093/cid/ciy358.

8.

Fecal Microbiome Among Nursing Home Residents with Advanced Dementia and Clostridium difficile.

Araos R, Andreatos N, Ugalde J, Mitchell S, Mylonakis E, D'Agata EMC.

Dig Dis Sci. 2018 Jun;63(6):1525-1531. doi: 10.1007/s10620-018-5030-7. Epub 2018 Mar 28.

9.

[Safety of fluoroquinolones: risks usually forgotten for the clinician].

González M C, Rosales C R, Pavez D, Fuenzalida LM, Soto A, Pérez R, Pérez J, Araos R, Pinto ME.

Rev Chilena Infectol. 2017 Dec;34(6):577-582. doi: 10.4067/S0716-10182017000600577. Spanish.

10.

[Leprosy: we figth the disease not those who suffer from it].

Vial PA, Araos R.

Rev Chilena Infectol. 2017 Aug;34(4):305-306. doi: 10.4067/s0716-10182017000400305. Spanish. No abstract available.

11.

Microbial Disruption Indices to Detect Colonization With Multidrug-Resistant Organisms.

Araos R, Montgomery V, Ugalde JA, Snyder GM, D'Agata EMC.

Infect Control Hosp Epidemiol. 2017 Nov;38(11):1312-1318. doi: 10.1017/ice.2017.190. Epub 2017 Sep 13.

12.

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, Lichtenberger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA.

Clin Infect Dis. 2017 Jul 1;65(1):158-161. doi: 10.1093/cid/cix014.

13.

Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms.

Araos R, Tai AK, Snyder GM, Blaser MJ, D'Agata EMC.

Clin Infect Dis. 2016 Oct 1;63(7):937-943. doi: 10.1093/cid/ciw426. Epub 2016 Jun 28.

14.

[Daptomycin: pharmacological characteristics and its role in the treatment of gram positive infections].

Araos R, García P, Chanqueo L, Labarca J.

Rev Chilena Infectol. 2012 Apr;29(2):127-31. doi: 10.4067/S0716-10182012000200001. Review. Spanish.

15.

Pandemic influenza A (H1N1) 2009 with neurological manifestations, a case series.

Noriega LM, Verdugo RJ, Araos R, Munita JM, Díaz V, Marcotti A, Perez J, Gonzalez P, Thompson L, Canals M, Hoppe A, Mounts AW, Vial PA.

Influenza Other Respir Viruses. 2010 May 1;4(3):117-20. doi: 10.1111/j.1750-2659.2010.00131.x.

16.

The result patterns of ML Flow and ELISA (PGL-I) serologic tests in leprosy-endemic and non-endemic areas.

Silva RC, Lyon S, Araos R, Lyon AC, Grossi MA, Lyon SH, Penido RA, Bührer-Sékula S, Antunes CM.

Rev Soc Bras Med Trop. 2008;41 Suppl 2:19-22.

Supplemental Content

Support Center